The Experts below are selected from a list of 153 Experts worldwide ranked by ideXlab platform
Cheng Yang - One of the best experts on this subject based on the ideXlab platform.
-
Correlation between MDSC and Immune Tolerance in Transplantation: Cytokines, Pathways and Cell-cell interaction.
Current gene therapy, 2019Co-Authors: Tianying Yang, Chunchen Yang, Weitao Zhang, Yue Qiu, Cheng Yang, Ruiming RongAbstract:MDSCs play an important role in the induction of immune Tolerance. Cytokines and chemokines (GM-CSF, IL-6) contributed to the expansion, accumulation of MDSCs, and MDSCs function through inOS, arginase and PD-L1. MDSCs are recruited and regulated through JAK/STAT, mTOR and Raf/MEK/ERK signaling pathways. MDSCs' immunosuppressive functions were realized through Tregs-mediated pathways and their direct suppression of immune cells. All of the above contribute to the MDSC-related immune Tolerance in Transplantation. MDSCs have huge potential in prolonging graft survival and reducing rejection through different ways and many other factors worthy to be further investigated are also introduced.
-
Myeloid-derived suppressor cells in Transplantation: the dawn of cell therapy.
Journal of translational medicine, 2018Co-Authors: Weitao Zhang, Cheng YangAbstract:Myeloid-derived suppressor cells (MDSCs) are a series of innate cells that play a significant role in inhibiting T cell-related responses. This heterogeneous population of immature cells is involved in tumor immunity. Recently, the function and importance of MDSCs in Transplantation have garnered the attention of scientists and have become an important focus of Transplantation immunology research because MDSCs play a key role in establishing immune Tolerance in Transplantation. in this review, we summarize recent studies of MDSCs in different types of Transplantation. We also focus on the influence of immunosuppressive drugs on MDSCs as well as future obstacles and research directions in this field.
-
regulatory b cells the cutting edge of immune Tolerance in kidney Transplantation
Cell Death and Disease, 2018Co-Authors: Bo Peng, Yingzi Ming, Cheng YangAbstract:Kidney Transplantation is the optimal treatment for end-stage renal diseases. Although great improvement has been achieved, immune Tolerance is still the Holy Grail that every organ transplant practitioner pursues. The role of B cells in Transplantation has long been considered simply to serve as precursors of plasma cells, which produce alloantibodies and induce antibody-mediated rejection. Recent research indicates that a specialized subset of B cells plays an important role in immune regulation, which has been well demonstrated in autoimmune diseases, infections, and cancers. This category of regulatory B cells (Bregs) differs from conventional B cells, and they may help develop a novel immunomodulatory therapeutic strategy to achieve immune Tolerance in Transplantation. Here, we review the latest evidence regarding phenotypes, functions, and effectors of Bregs and discuss their diverse effects on kidney Transplantation.
-
The Crosstalk between Myeloid Derived Suppressor Cells and Immune Cells: To Establish Immune Tolerance in Transplantation
Journal of immunology research, 2016Co-Authors: Chao Zhang, Cheng Yang, Shuo Wang, Ruiming RongAbstract:Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of myeloid precursor and progenitor cells and endowed with a robust immunosuppressive activity in multiple pathophysiological conditions. Recent studies have uncovered the crosstalk between MDSCs and immune cells (i.e., natural killer cells, dendritic cells, macrophages, natural killer T cells, and regulatory T cells) and its role in the establishment and maintenance of immune tolerant microenvironment in Transplantation. Considering their strong immunosuppressive capability, MDSCs could become a prospective clinical regimen during Transplantation Tolerance induction, resulting in long-term graft survival with decreased or without immunosuppressive drugs. The review summarized recent research advances in this field and looked ahead at the research directions in the future.
Robert I. Lechler - One of the best experts on this subject based on the ideXlab platform.
-
regulatory t cells serious contenders in the promise for immunological Tolerance in Transplantation
Frontiers in Immunology, 2015Co-Authors: Niloufar Safinia, Robert I. Lechler, Cristiano Scotta, Trishan Vaikunthanathan, Giovanna LombardiAbstract:Regulatory T cells (Tregs) play an important role in immunoregulation and have been shown in animal models to promote Transplantation Tolerance and curb autoimmunity following their adoptive transfer. The safety and potential therapeutic efficacy of these cells has already been reported in Phase I trials of bone marrow Transplantation and type I diabetes, the success of which has motivated the broadened application of these cells in solid organ Transplantation. Despite major advances in the clinical translation of these cells, there are still key questions to be addressed to ensure that Tregs attest their reputation as ideal candidates for Tolerance induction. in this review, we will discuss the unique traits of Tregs that have attracted such fame in the arena of Tolerance induction. We will outline the protocols used for their ex vivo expansion and discuss the future directions of Treg cell therapy. in this regard, we will review the concept of Treg heterogeneity, the desire to isolate and expand a functionally superior Treg population and report on the effect of differing culture conditions. The relevance of Treg migratory capacity will also be discussed together with methods of in vivo visualization of the infused cells. Moreover, we will highlight key advances in the identification and expansion of antigen specific Tregs and discuss their significance for cell therapy application. We will also summarize the clinical parameters that are of importance, alongside cell manufacture, from the choice of immunosuppression regimens to the number of injections in order to direct the success of future efficacy trials of Treg cell therapy. Years of research in the field of Tolerance have seen an accumulation of knowledge and expertise in the field of Treg biology. This perpetual progression has been the driving force behind the many successes to date and has put us now within touching distance of our ultimate success, immunological Tolerance.
-
A 'biomarker signature' for Tolerance in Transplantation
Nature Reviews Nephrology, 2010Co-Authors: Maria P. Hernandez-fuentes, Robert I. LechlerAbstract:A critical gap in the field of Transplantation Tolerance is the lack of available tests or biomarkers to indicate when a patient has become partially or totally tolerant to their graft. Here, Hernandez-Fuentes and Lechler discuss advances in the development of biomarkers of Transplantation Tolerance and describe the potential utility of such biomarkers for the modification of protocols in clinical practice. in the past decade, an explosion in the number of high-throughput tools for the measurement of different cellular products has occurred. These tools have the potential to further our understanding of human disease and this development has facilitated the identification of new biomarkers in all areas of medicine. in the field of solid organ Transplantation, two different areas have developed: the use of biomarkers to predict allograft Tolerance for the identification of patients who can be weaned from immunosuppressive therapy, and biomarkers for the prediction of allograft rejection, so that parenchymal damage can be prevented before it becomes irreversible. in this Review, we discuss the development of biomarkers that are indicative of transplant Tolerance. Identifying patients in whom donor-specific Tolerance has developed would constitute a major advance in the care of organ transplant recipients. This ability would allow the minimization or even the withdrawal of immunosuppressive therapy in selected patients, thus reducing the number of adverse effects and costs, and optimizing long-term graft outcomes. The routine clinical use of these biomarkers, once validated, would bring to the fore the possibility of personalized medicine. The use of biomarkers may allow the possibility of personalized medicine in fields such as renal Transplantation in the follow-up of solid organ transplant recipients, validated biomarkers of Tolerance may be as clinically useful as biomarkers of rejection Biomarkers of Tolerance may be used in the future to identify patients in whom immunosuppression can be weaned or even withdrawn Such biomarkers could also be used to establish the success of Tolerance-inducing protocols Cross-platform biomarkers may be more effective at identifying Tolerance than single biomarkers
-
a biomarker signature for Tolerance in Transplantation
Nature Reviews Nephrology, 2010Co-Authors: Maria P Hernandezfuentes, Robert I. LechlerAbstract:A critical gap in the field of Transplantation Tolerance is the lack of available tests or biomarkers to indicate when a patient has become partially or totally tolerant to their graft. Here, Hernandez-Fuentes and Lechler discuss advances in the development of biomarkers of Transplantation Tolerance and describe the potential utility of such biomarkers for the modification of protocols in clinical practice. in the past decade, an explosion in the number of high-throughput tools for the measurement of different cellular products has occurred. These tools have the potential to further our understanding of human disease and this development has facilitated the identification of new biomarkers in all areas of medicine. in the field of solid organ Transplantation, two different areas have developed: the use of biomarkers to predict allograft Tolerance for the identification of patients who can be weaned from immunosuppressive therapy, and biomarkers for the prediction of allograft rejection, so that parenchymal damage can be prevented before it becomes irreversible. in this Review, we discuss the development of biomarkers that are indicative of transplant Tolerance. Identifying patients in whom donor-specific Tolerance has developed would constitute a major advance in the care of organ transplant recipients. This ability would allow the minimization or even the withdrawal of immunosuppressive therapy in selected patients, thus reducing the number of adverse effects and costs, and optimizing long-term graft outcomes. The routine clinical use of these biomarkers, once validated, would bring to the fore the possibility of personalized medicine.
-
A 'biomarker signature' for Tolerance in Transplantation
Nature reviews. Nephrology, 2010Co-Authors: Maria P. Hernandez-fuentes, Robert I. LechlerAbstract:in the past decade, an explosion in the number of high-throughput tools for the measurement of different cellular products has occurred. These tools have the potential to further our understanding of human disease and this development has facilitated the identification of new biomarkers in all areas of medicine. in the field of solid organ Transplantation, two different areas have developed: the use of biomarkers to predict allograft Tolerance for the identification of patients who can be weaned from immunosuppressive therapy, and biomarkers for the prediction of allograft rejection, so that parenchymal damage can be prevented before it becomes irreversible. in this Review, we discuss the development of biomarkers that are indicative of transplant Tolerance. Identifying patients in whom donor-specific Tolerance has developed would constitute a major advance in the care of organ transplant recipients. This ability would allow the minimization or even the withdrawal of immunosuppressive therapy in selected patients, thus reducing the number of adverse effects and costs, and optimizing long-term graft outcomes. The routine clinical use of these biomarkers, once validated, would bring to the fore the possibility of personalized medicine.
Ruiming Rong - One of the best experts on this subject based on the ideXlab platform.
-
Correlation between MDSC and Immune Tolerance in Transplantation: Cytokines, Pathways and Cell-cell interaction.
Current gene therapy, 2019Co-Authors: Tianying Yang, Chunchen Yang, Weitao Zhang, Yue Qiu, Cheng Yang, Ruiming RongAbstract:MDSCs play an important role in the induction of immune Tolerance. Cytokines and chemokines (GM-CSF, IL-6) contributed to the expansion, accumulation of MDSCs, and MDSCs function through inOS, arginase and PD-L1. MDSCs are recruited and regulated through JAK/STAT, mTOR and Raf/MEK/ERK signaling pathways. MDSCs' immunosuppressive functions were realized through Tregs-mediated pathways and their direct suppression of immune cells. All of the above contribute to the MDSC-related immune Tolerance in Transplantation. MDSCs have huge potential in prolonging graft survival and reducing rejection through different ways and many other factors worthy to be further investigated are also introduced.
-
The Crosstalk between Myeloid Derived Suppressor Cells and Immune Cells: To Establish Immune Tolerance in Transplantation
Journal of immunology research, 2016Co-Authors: Chao Zhang, Cheng Yang, Shuo Wang, Ruiming RongAbstract:Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of myeloid precursor and progenitor cells and endowed with a robust immunosuppressive activity in multiple pathophysiological conditions. Recent studies have uncovered the crosstalk between MDSCs and immune cells (i.e., natural killer cells, dendritic cells, macrophages, natural killer T cells, and regulatory T cells) and its role in the establishment and maintenance of immune tolerant microenvironment in Transplantation. Considering their strong immunosuppressive capability, MDSCs could become a prospective clinical regimen during Transplantation Tolerance induction, resulting in long-term graft survival with decreased or without immunosuppressive drugs. The review summarized recent research advances in this field and looked ahead at the research directions in the future.
Weitao Zhang - One of the best experts on this subject based on the ideXlab platform.
-
Correlation between MDSC and Immune Tolerance in Transplantation: Cytokines, Pathways and Cell-cell interaction.
Current gene therapy, 2019Co-Authors: Tianying Yang, Chunchen Yang, Weitao Zhang, Yue Qiu, Cheng Yang, Ruiming RongAbstract:MDSCs play an important role in the induction of immune Tolerance. Cytokines and chemokines (GM-CSF, IL-6) contributed to the expansion, accumulation of MDSCs, and MDSCs function through inOS, arginase and PD-L1. MDSCs are recruited and regulated through JAK/STAT, mTOR and Raf/MEK/ERK signaling pathways. MDSCs' immunosuppressive functions were realized through Tregs-mediated pathways and their direct suppression of immune cells. All of the above contribute to the MDSC-related immune Tolerance in Transplantation. MDSCs have huge potential in prolonging graft survival and reducing rejection through different ways and many other factors worthy to be further investigated are also introduced.
-
Myeloid-derived suppressor cells in Transplantation: the dawn of cell therapy.
Journal of translational medicine, 2018Co-Authors: Weitao Zhang, Cheng YangAbstract:Myeloid-derived suppressor cells (MDSCs) are a series of innate cells that play a significant role in inhibiting T cell-related responses. This heterogeneous population of immature cells is involved in tumor immunity. Recently, the function and importance of MDSCs in Transplantation have garnered the attention of scientists and have become an important focus of Transplantation immunology research because MDSCs play a key role in establishing immune Tolerance in Transplantation. in this review, we summarize recent studies of MDSCs in different types of Transplantation. We also focus on the influence of immunosuppressive drugs on MDSCs as well as future obstacles and research directions in this field.
Joost P. M. Van Meerwijk - One of the best experts on this subject based on the ideXlab platform.
-
Hematopoietic chimerism and Transplantation Tolerance: a role for regulatory T cells.
Frontiers in immunology, 2011Co-Authors: Lise Pasquet, Olivier Joffre, Thibault Santolaria, Joost P. M. Van MeerwijkAbstract:The major obstacle in Transplantation medicine is rejection of donor tissues by the host’s immune system. Immunosuppressive drugs can delay but not prevent loss of transplants, and their efficiency is strongly impacted by inter-individual pharmacokinetic differences. Moreover, due to the global immunosuppression induced and to the broad distribution of their targets amongst human tissues, these drugs have severe side effects. induction of donor-specific non-responsiveness (i.e. immunological Tolerance) to transplants would solve these problems and would substantially ameliorate patients’ quality of life. It is widely believed that bone marrow or hematopoietic stem cell Transplantation, and resulting (mixed) hematopoietic chimerism, invariably leads to immunological Tolerance to organs of the same donor. A careful analysis of the literature, reviewed here, indeed shows that chimerism consistently prolongs allograft survival. However, in absence of additional conditioning leading to the development of active regulatory mechanisms, it does not prevent chronic rejection. A central role for active Tolerance in Transplantation-Tolerance is also supported by recent data showing that genuine immunological Tolerance to organ allografts can be achieved by combining induction of hematopoietic chimerism with infusion of regulatory T lymphocytes. Therefore, conditioning regimens that lead to the establishment of hematopoietic chimerism plus active regulatory mechanisms appear required for induction of genuine Tolerance to allogeneic grafts.